financetom
Business
financetom
/
Business
/
KBR Credit Rating Raised One Notch to BB+ by S&P Global, Citing Improved Metrics, Likely Benefits of LinQuest Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KBR Credit Rating Raised One Notch to BB+ by S&P Global, Citing Improved Metrics, Likely Benefits of LinQuest Deal
Aug 16, 2024 1:27 PM

04:10 PM EDT, 08/16/2024 (MT Newswires) -- KBR (KBR) closed nearly 1% lower, easing from a small gain earlier Friday, after S&P Global Ratings raised its credit rating by one notch to BB+ from BB previously, citing improved credit metrics at the large-scale construction and engineering company.

Revenue and margins for KBR's earnings before interest, taxes, depreciation and amortization have been growing during 2024, the S&P analysts said, pointing to its $737 million acquisition of aerospace contractor LinQuest announced on July 16. The deal also should eventually deliver better EBITDA- and funds from operations-to-debt ratios, although it may take a year or so for those benefits to fully arrive, they said.

The ratings firm also believes LinQuest will strengthen KBR's relationship with customers in its government solutions segment and allow the company to tap into its internal capabilities to fulfill portions of its contracts instead of relying on subcontractors, bolstering profits.

S&P's overall outlook for KBR was stable.

Price: 65.45, Change: +0.01, Percent Change: +0.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Crescent Capital's Q3 NAV per share falls
Crescent Capital's Q3 NAV per share falls
Nov 12, 2025
Overview * Crescent Capital BDC ( CCAP ) Q3 net investment income per share was $0.46, unchanged from Q2 * Net asset value per share declines to $19.28 from $20.20 year-over-year * Company declares Q4 regular cash dividend of $0.42 per share Outlook * Company has $239.8 mln undrawn capacity on credit facilities * Weighted average cost of debt is...
BioRestorative Therapies' Q3 revenue drops, net loss widens
BioRestorative Therapies' Q3 revenue drops, net loss widens
Nov 12, 2025
Overview * BioRestorative Q3 2025 revenue declines significantly compared to Q3 2024 * Company reports Q3 net loss of $3 mln, up from $1 mln in Q3 2024 * BioRestorative strengthens financial position with recent stock offering and private placement Outlook * Company focuses on near-term revenue strategy in BioCosmeceutical platform * BioRestorative aims to expand BioCosmeceutical offerings for FDA...
GRAIL Q3 Loss Narrows, Revenue Rises
GRAIL Q3 Loss Narrows, Revenue Rises
Nov 12, 2025
04:33 PM EST, 11/12/2025 (MT Newswires) -- GRAIL (GRAL) reported a Q3 net loss late Wednesday of $2.46 per diluted share, narrowing from the loss of $3.94 a year earlier. Four analysts polled by FactSet expected a loss of $3.37. Revenue in the three months ended Sept. 30 rose to $36.2 million from $28.7 million a year earlier. Three analysts...
Lyell Immunopharma Q3 adjusted net loss beats estimates
Lyell Immunopharma Q3 adjusted net loss beats estimates
Nov 12, 2025
Overview * Lyell Q3 adjusted net loss beats analyst expectations * Company acquired global rights to LYL273, a GCC-targeted CAR T-cell product * Initiated PiNACLE - H2H Phase 3 trial for aggressive large B-cell lymphoma Outlook * Company expects to begin PiNACLE - H2H trial enrollment by early 2026 * Lyell anticipates LYL273 Phase 1 trial data update in H1...
Copyright 2023-2026 - www.financetom.com All Rights Reserved